TAKEDA PHARMACEUTIC-SP ADR (TAK) Fundamental Analysis & Valuation

NYSE:TAK • US8740602052

Current stock price

16.36 USD
-0.27 (-1.62%)
Last:

This TAK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. TAK Profitability Analysis

1.1 Basic Checks

  • TAK had positive earnings in the past year.
  • In the past year TAK had a positive cash flow from operations.
  • In the past 5 years TAK has always been profitable.
  • TAK had a positive operating cash flow in each of the past 5 years.
TAK Yearly Net Income VS EBIT VS OCF VS FCFTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B 1T

1.2 Ratios

  • The Return On Assets of TAK (0.73%) is better than 81.15% of its industry peers.
  • TAK has a Return On Equity of 1.48%. This is amongst the best in the industry. TAK outperforms 82.20% of its industry peers.
  • With a decent Return On Invested Capital value of 2.32%, TAK is doing good in the industry, outperforming 79.58% of the companies in the same industry.
  • TAK had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 13.10%.
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROIC 2.32%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
TAK Yearly ROA, ROE, ROICTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

1.3 Margins

  • With an excellent Profit Margin value of 2.53%, TAK belongs to the best of the industry, outperforming 81.68% of the companies in the same industry.
  • In the last couple of years the Profit Margin of TAK has grown nicely.
  • TAK has a Operating Margin of 10.76%. This is amongst the best in the industry. TAK outperforms 82.72% of its industry peers.
  • In the last couple of years the Operating Margin of TAK has grown nicely.
  • TAK has a better Gross Margin (65.33%) than 71.73% of its industry peers.
  • TAK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
TAK Yearly Profit, Operating, Gross MarginsTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TAK Health Analysis

2.1 Basic Checks

  • TAK has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • TAK has more shares outstanding than it did 1 year ago.
  • TAK has more shares outstanding than it did 5 years ago.
  • TAK has a better debt/assets ratio than last year.
TAK Yearly Shares OutstandingTAK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
TAK Yearly Total Debt VS Total AssetsTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T

2.2 Solvency

  • TAK has an Altman-Z score of 1.18. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
  • TAK has a Altman-Z score of 1.18. This is comparable to the rest of the industry: TAK outperforms 51.83% of its industry peers.
  • TAK has a debt to FCF ratio of 6.48. This is a slightly negative value and a sign of low solvency as TAK would need 6.48 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 6.48, TAK belongs to the best of the industry, outperforming 81.68% of the companies in the same industry.
  • TAK has a Debt/Equity ratio of 0.56. This is a neutral value indicating TAK is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.56, TAK is not doing good in the industry: 68.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Altman-Z 1.18
ROIC/WACC1.42
WACC1.63%
TAK Yearly LT Debt VS Equity VS FCFTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2T 4T 6T

2.3 Liquidity

  • A Current Ratio of 1.19 indicates that TAK should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.19, TAK is doing worse than 81.68% of the companies in the same industry.
  • TAK has a Quick Ratio of 1.19. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • TAK has a Quick ratio of 0.65. This is amonst the worse of the industry: TAK underperforms 89.53% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.65
TAK Yearly Current Assets VS Current LiabilitesTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500B 1T 1.5T 2T 2.5T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TAK Growth Analysis

3.1 Past

  • The earnings per share for TAK have decreased strongly by -45.17% in the last year.
  • TAK shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.20% yearly.
  • Looking at the last year, TAK shows a decrease in Revenue. The Revenue has decreased by -2.50% in the last year.
  • The Revenue has been growing slightly by 6.84% on average over the past years.
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%

3.2 Future

  • TAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.51% yearly.
  • Based on estimates for the next years, TAK will show a small growth in Revenue. The Revenue will grow by 0.47% on average per year.
EPS Next Y77.07%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
EPS Next 5YN/A
Revenue Next Year-1.08%
Revenue Next 2Y0.06%
Revenue Next 3Y0.47%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TAK Yearly Revenue VS EstimatesTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
TAK Yearly EPS VS EstimatesTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 -50 100

More info and screens

Find the best growth stocksShow best growing peers

6

4. TAK Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 71.13, TAK can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, TAK is valued a bit cheaper than 78.01% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.42, TAK is valued quite expensively.
  • A Price/Forward Earnings ratio of 29.04 indicates a quite expensive valuation of TAK.
  • Based on the Price/Forward Earnings ratio, TAK is valued a bit cheaper than the industry average as 74.87% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 22.29. TAK is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 71.13
Fwd PE 29.04
TAK Price Earnings VS Forward Price EarningsTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • TAK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TAK is cheaper than 88.48% of the companies in the same industry.
  • TAK's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TAK is cheaper than 89.53% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.01
EV/EBITDA 10.07
TAK Per share dataTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of TAK may justify a higher PE ratio.
  • TAK's earnings are expected to grow with 44.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.92
PEG (5Y)3.71
EPS Next 2Y62.14%
EPS Next 3Y44.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. TAK Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.75%, TAK has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 0.73, TAK pays a better dividend. On top of this TAK pays more dividend than 95.81% of the companies listed in the same industry.
  • TAK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 3.75%

5.2 History

  • The dividend of TAK has a limited annual growth rate of 1.18%.
  • TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years3
Div Non Decr Years4
TAK Yearly Dividends per shareTAK Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 50 100 150

5.3 Sustainability

  • TAK pays out 277.04% of its income as dividend. This is not a sustainable payout ratio.
  • TAK's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP277.04%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
TAK Yearly Income VS Free CF VS DividendTAK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B
TAK Dividend Payout.TAK Dividend Payout, showing the Payout Ratio.TAK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

TAK Fundamentals: All Metrics, Ratios and Statistics

TAKEDA PHARMACEUTIC-SP ADR

NYSE:TAK (4/27/2026, 4:10:00 PM)

16.36

-0.27 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-30
Earnings (Next)05-13
Inst Owners48.8%
Inst Owner Change-0.04%
Ins Owners0%
Ins Owner Change0%
Market Cap51.68B
Revenue(TTM)4.46T
Net Income(TTM)112.93B
Analysts74.74
Price Target20.07 (22.68%)
Short Float %0.22%
Short Ratio2.34
Dividend
Industry RankSector Rank
Dividend Yield 3.75%
Yearly Dividend0.6
Dividend Growth(5Y)1.18%
DP277.04%
Div Incr Years3
Div Non Decr Years4
Ex-Date03-30
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-121.92%
Max EPS beat(2)90.61%
EPS beat(4)2
Avg EPS beat(4)-2.37%
Min EPS beat(4)-121.92%
Max EPS beat(4)90.61%
EPS beat(8)4
Avg EPS beat(8)-37%
EPS beat(12)6
Avg EPS beat(12)-26.29%
EPS beat(16)8
Avg EPS beat(16)-33.22%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-6.04%
Max Revenue beat(2)0.21%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)0.21%
Revenue beat(8)4
Avg Revenue beat(8)1.91%
Revenue beat(12)7
Avg Revenue beat(12)2.79%
Revenue beat(16)11
Avg Revenue beat(16)3.3%
PT rev (1m)10.43%
PT rev (3m)21.52%
EPS NQ rev (1m)-1.09%
EPS NQ rev (3m)-17.21%
EPS NY rev (1m)1.43%
EPS NY rev (3m)1.69%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)2.93%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.7%
Valuation
Industry RankSector Rank
PE 71.13
Fwd PE 29.04
P/S 1.85
P/FCF 11.01
P/OCF 6.93
P/B 1.08
P/tB N/A
EV/EBITDA 10.07
EPS(TTM)0.23
EY1.41%
EPS(NY)0.56
Fwd EY3.44%
FCF(TTM)1.49
FCFY9.09%
OCF(TTM)2.36
OCFY14.43%
SpS8.86
BVpS15.18
TBVpS-3.23
PEG (NY)0.92
PEG (5Y)3.71
Graham Number8.86195 (-45.83%)
Profitability
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROCE 3.75%
ROIC 2.32%
ROICexc 2.47%
ROICexgc 10.72%
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
FCFM 16.77%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
ROICexc(3y)2.79%
ROICexc(5y)2.75%
ROICexgc(3y)14.77%
ROICexgc(5y)14.24%
ROCE(3y)4.3%
ROCE(5y)4.17%
ROICexgc growth 3Y-5.18%
ROICexgc growth 5Y8.79%
ROICexc growth 3Y-2.83%
ROICexc growth 5Y11.44%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Debt/EBITDA 3.48
Cap/Depr 58.95%
Cap/Sales 9.86%
Interest Coverage 4.11
Cash Conversion 96.87%
Profit Quality 663%
Current Ratio 1.19
Quick Ratio 0.65
Altman-Z 1.18
F-Score5
WACC1.63%
ROIC/WACC1.42
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
EPS Next Y77.07%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%
Revenue Next Year-1.08%
Revenue Next 2Y0.06%
Revenue Next 3Y0.47%
Revenue Next 5YN/A
EBIT growth 1Y0.22%
EBIT growth 3Y0.56%
EBIT growth 5Y14.13%
EBIT Next Year442.96%
EBIT Next 3Y77.92%
EBIT Next 5YN/A
FCF growth 1Y680.23%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y62.56%
OCF growth 3Y-2%
OCF growth 5Y9.54%

TAKEDA PHARMACEUTIC-SP ADR / TAK Fundamental Analysis FAQ

What is the fundamental rating for TAK stock?

ChartMill assigns a fundamental rating of 5 / 10 to TAK.


What is the valuation status for TAK stock?

ChartMill assigns a valuation rating of 6 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.


How profitable is TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 8 / 10.


What is the earnings growth outlook for TAKEDA PHARMACEUTIC-SP ADR?

The Earnings per Share (EPS) of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to grow by 77.07% in the next year.


Is the dividend of TAKEDA PHARMACEUTIC-SP ADR sustainable?

The dividend rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 6 / 10 and the dividend payout ratio is 277.04%.